COSMOS Pharmaceutical Corporation
CSMYFOTCHealthcare● Active
$41.20
+$4.14(+11.17%)
Market Cap$3.3B
P/E Ratio—
52W High$48.271
52W Low$37.06
COSMOS Pharmaceutical Corporation (CSMYF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSMYF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-05 | 2024-05 | 2023-05 | 2022-05 | 2021-05 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.011T | $0.965T | $0.828T | $0.755T | $0.726T |
| Cost of Revenue | $0.798T | $0.777T | $0.659T | $0.604T | $0.581T |
| Gross Profit | $0.213T | $0.188T | $0.169T | $0.151T | $0.145T |
| Gross Margin %(computed) | 21.09% | 19.51% | 20.38% | 20.05% | 19.98% |
| Operating Expenses | |||||
| R&D Expenses | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| G&A Expenses | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Total Operating Expenses | $0.173T | $0.157T | $0.139T | $0.122T | $0.112T |
| Operating Income | $0.040T | $0.032T | $0.030T | $0.030T | $0.033T |
| Operating Margin %(computed) | 3.99% | 3.26% | 3.64% | 3.94% | 4.56% |
| Interest Income | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Interest Expense | $0.000T | $0.000T | $0.000T | $0.000T | $0.000T |
| Income Before Tax | $0.042T | $0.034T | $0.033T | $0.033T | $0.039T |
| Income Tax Expense | $0.011T | $0.009T | $0.009T | $0.010T | $0.011T |
| Net Income | $0.031T | $0.024T | $0.024T | $0.023T | $0.027T |
| Net Margin %(computed) | 3.06% | 2.53% | 2.88% | 3.07% | 3.74% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $390.86 | $308.61 | $600.95 | $584.74 | $685.77 |
| Wtd Avg Shares | 0.000T | 0.000T | 0.000T | 0.000T | 0.000T |
| EBITDA | $0.065T | $0.054T | $0.050T | $0.048T | $0.052T |
| EBITDA Margin %(computed) | 6.41% | 5.57% | 6.06% | 6.38% | 7.22% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · T
Explore more COSMOS Pharmaceutical Corporation data
About COSMOS Pharmaceutical Corporation (CSMYF) Income Statement
COSMOS Pharmaceutical Corporation (CSMYF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSMYF reported revenue of $1011.39B, gross profit of $213.28B (gross margin 21.09%), and net income of $30.98B — a net profit margin of 3.06%.
Frequently asked questions
CSMYF · 4 questionsCOSMOS Pharmaceutical Corporation (CSMYF) reported revenue of $1011.39B for 2025, up 4.8% year-over-year.
CSMYF revenueCSMYF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09